Exactus seeking prime position in hemp cannabinoids
Following enactment of ‘the Farm Bill’ in the US in January 2019, legalising hemp cultivation and opening the door to potential huge market growth for hemp-derived CBD (cannabidiol), CBD sales in the US are projected to increase from US$291mln in 2017 to US$5.7bn by 2019, based on a myriad of well-being and health applications. Exactus (EXDI) intends to carve out a leading position in the burgeoning CBD market by establishing control over the entire chain of custody for CBD production ‘from seed to consumer’ to provide full traceability and quality assurance on its products.
Quick facts: Exactus, Inc.
Price: 0.41 USD
Market Cap: $16.66 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Exactus, Inc. named herein, including the promotion by the Company of Exactus, Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE